Gus, Buy out or buy access are possibilities, but those are not my first choice. I am optimistic to find out what the "franchise" commercialization will be.
For example, if every approved cancer drug out there today, can be optimized (add immune memory) and or have their toxicity reduced (same efficacy but fewer doses) by adding DCVax to their therapy, then that would be the ideal and optimized situation for NWBO, IMO.
DCVax would be the base layer in combination therapy
- safest and optimizes others drugs
Other cancer drugs would be distribution channels for DCVax.
NWBO would maximize its own product revenues. We sell DCVax, as opposed to sell out or turn it into the much smaller fractional royalty payments.
On stock price, investors looks forward. So I believe institutional investors will recognize and reward that.
Market Data 
Markets 
AI
